<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28277">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01720316</url>
  </required_header>
  <id_info>
    <org_study_id>2012p001597</org_study_id>
    <secondary_id>R21MH097470-01A1</secondary_id>
    <nct_id>NCT01720316</nct_id>
  </id_info>
  <brief_title>Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders</brief_title>
  <official_title>Pilot Study of Glycine Augmentation in Carriers of a Mutation in the Gene Encoding Glycine Decarboxylase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mclean Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mclean Hospital</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of oral glycine as an augmentation
      strategy in two psychotic patients with a triplication (4 copies) of the gene glycine
      decarboxylase (GLDC). Subjects will first undergo a double-blind placebo-controlled clinical
      trial in which one 6-week arm will involve glycine (maximum daily dose of 0.8 g/kg,
      administered on a TID dosing schedule) and one 6-week arm will involve placebo. A 2-week
      period of no treatment will occur between treatment arms.  A 6-week period of open-label
      glycine (maximum daily dose of 0.8 g/kg, administered on a TID dosing schedule) will follow
      the double-blind placebo-controlled clinical trial. Prior to the double-blind
      placebo-controlled clinical trial and at the end of the open-label glycine trial, the
      following procedures will be carried out:  structural MRI (3T), Proton 1H MRS (4T), fMRI
      (3T), steady-state visual evoked potentials, and EEG. Positive, negative, and affective
      symptoms and neurocognitive function as well as plasma levels of large neutral and large and
      small neutral and excitatory amino acids and psychotropic drug levels will be assessed
      periodically. In addition, 1H MRS (4T) for 2 hours after a single oral dose of a
      glycine-containing drink will be assessed at baseline. Pharmaceutical grade glycine powder
      (Ajinomoto) or placebo will be dissolved in 20% solution and prepared by the McLean Hospital
      Pharmacy.

      The investigators hypothesize that mutation carriers will have reduced endogenous brain
      glycine and GABA levels and increased brain glutamate and glutamine levels. Glycine
      administration will increase brain glycine in the two carriers, but to a lesser extent than
      in non-carrier family members and controls.

      The investigators hypothesize reduced activation of magnocellular pathways and abnormal ERPs
      modulated by NMDA in mutation carriers compared with non-carrier family members and
      controls.

      The investigators hypothesize that glycine, but not placebo, will improve positive, negative
      and affective symptoms as well as neurocognitive function.

      The investigators also hypothesize that open-label glycine will improve clinical and
      cognitive functioning, will partially normalize decreased baseline glycine and GABA and
      increased glutamate and glutamine, and will partially normalize magnocellular pathway
      activation and abnormal evoked potentials.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple rare structural variants of relatively recent evolutionary origin are recognized as
      important risk factors for schizophrenia (SZ) and other neurodevelopmental disorders (e.g.,
      autism spectrum disorders, mental retardation, epilepsy) with odds ratios as high as 7-30
      (Sebat et al. 2009; Malhotra et al. 2011; Heinzen et al. 2010; Weiss et al. 2008; McCarthy
      et al. 2009). We have found a de novo structural rearrangement on chromosome 9p24.1 in two
      psychotic patients.  One of the genes in this region is the gene encoding glycine
      decarboxylase (GLDC), which affects brain glycine metabolism. GLDC encodes the glycine
      decarboxylase or glycine cleavage system P-protein, which is involved in degradation of
      glycine in glia cells.  Carriers of the GLDC triplication would be expected to have low
      levels of brain Gly, resulting in NMDA receptor-mediated hypofunction, which has been
      strongly implicated in the pathophysiology of schizophrenia (Olney &amp; Farber, 1995; Coyle,
      2006; Javitt, 2007).

      There is an extensive literature on the effects of NMDA enhancing agents on positive,
      negative, and depressive symptoms and on neurocognitive function (see Tsai &amp; Lin, 2010; Lin
      et al. 2011 for reviews).  Although many studies have reported positive results in at least
      one symptom domain (Heresco-Levy et al. 1996, 1999, 2004; Tsai et al. 1998, 1999, 2004,
      2006; Javitt et al. 2001; Goff et al. 1996; Lane et al. 2008), the results of other studies
      have been negative or ambiguous (Goff et al. 1999; Evins et al. 2000; Duncan et al. 2004;
      van Berckel et al. 1999). Factors likely to contribute to this variability include:
      mechanism of action of the agent, compliance, concurrent treatment with first- vs second
      generation antipsychotic drugs, baseline glycine blood levels, presence/absence of
      kynurenine pathway metabolic abnormalities (Wonodi et al. 2010; Erhardt et al. 2007) and
      individual differences in brain glycine uptake and metabolism (Kaufman et al. 2009; Buchanan
      et al. 2007). Genetic variants that impact the synthesis and breakdown of glycine,
      glutamate, or other modulators of NMDA receptor function are also likely to have significant
      effects.  Although glycine augmentation has shown variable efficacy in patients unselected
      for having a mutation that would be expected to lower brain glycine levels, the GLDC
      triplication in the two carriers in this study would be expected to result in unusually low
      brain glycine levels, supporting its therapeutic potential as an augmentation strategy.

      Thus, it is important to evaluate the therapeutic efficacy of glycine augmentation in
      individuals in whom there is a high prior probability of therapeutic benefit and to
      characterize the neurobiology of this mutation in terms of brain metabolites, brain
      function, and the pharmacokinetics of glycine metabolism using well-established methods
      (Kaufman et al. 2009; Prescot et al. 2006; Martinez et al. 2008; Butler et al. 2001; Jensen
      et al. 2009; Ongur et al. 2008).
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in positive and negative symptoms compared with baseline</measure>
    <time_frame>6 weeks per treatment arm</time_frame>
    <safety_issue>No</safety_issue>
    <description>Positive and Negative Symptom Scale (PANSS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in clinical functioning compared with baseline</measure>
    <time_frame>6 weeks per treatment arm</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical Global Impression (CGI) Scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in mood symptoms compared with baseline</measure>
    <time_frame>6 weeks per treatment arm</time_frame>
    <safety_issue>No</safety_issue>
    <description>Young Mania Scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in mood symptoms compared with baseline</measure>
    <time_frame>6 weeks per treatment arm</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hamilton Depression Scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change neurocognitive function compared with baseline</measure>
    <time_frame>6 weeks per treatment arm</time_frame>
    <safety_issue>No</safety_issue>
    <description>MATRICS battery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in symptoms compared with baseline</measure>
    <time_frame>6 weeks per treatment arm</time_frame>
    <safety_issue>No</safety_issue>
    <description>Brief Psychiatric Rating Scale (BPRS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change plasma amino acid levels compared with baseline</measure>
    <time_frame>6 weeks per treatment arm</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma amino acid levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in glycine metabolite levels post glycine treatment compared with baseline</measure>
    <time_frame>6 weeks per treatment arm</time_frame>
    <safety_issue>No</safety_issue>
    <description>spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glutamate metabolite levels post glycine treatment compared with baseline</measure>
    <time_frame>6 weeks per treatment arm</time_frame>
    <safety_issue>No</safety_issue>
    <description>spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in GABA metabolite levels post glycine treatment compared with baseline</measure>
    <time_frame>6 weeks per treatment arm</time_frame>
    <safety_issue>No</safety_issue>
    <description>spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glutamine metabolite levels post glycine treatment compared with baseline</measure>
    <time_frame>6 weeks per treatment arm</time_frame>
    <safety_issue>No</safety_issue>
    <description>spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in evoked potentials compared with baseline</measure>
    <time_frame>6 weeks per treatment arm</time_frame>
    <safety_issue>No</safety_issue>
    <description>evoked potentials</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in magnocellular pathway function compared with baseline</measure>
    <time_frame>6 weeks per treatment arm</time_frame>
    <safety_issue>No</safety_issue>
    <description>functional magnetic resonance imaging</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2</enrollment>
  <condition>Schizo-affective Disorder</condition>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>glycine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glycine powder, up to 0.8 g/kg, administered with TID dosing for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo, TID dosing, 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glycine powder</intervention_name>
    <description>Double-blind placebo controlled trial of glycine or placebo, followed by open-label glycine</description>
    <arm_group_label>glycine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Triplication of glycine decarboxylase gene

        Exclusion Criteria:

          -  Normal glycine decarboxylase copy number
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deborah L Levy, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mclean Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McLean Hospital</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Butler PD, Schechter I, Zemon V, Schwartz SG, Greenstein VC, Gordon J, Schroeder CE, Javitt DC. Dysfunction of early-stage visual processing in schizophrenia. Am J Psychiatry. 2001 Jul;158(7):1126-33.</citation>
    <PMID>11431235</PMID>
  </reference>
  <reference>
    <citation>Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, Heresco-Levy U, Carpenter WT. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry. 2007 Oct;164(10):1593-602.</citation>
    <PMID>17898352</PMID>
  </reference>
  <reference>
    <citation>Coyle JT. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol. 2006 Jul-Aug;26(4-6):365-84. Epub 2006 Jun 14. Review.</citation>
    <PMID>16773445</PMID>
  </reference>
  <reference>
    <citation>Duncan EJ, Szilagyi S, Schwartz MP, Bugarski-Kirola D, Kunzova A, Negi S, Stephanides M, Efferen TR, Angrist B, Peselow E, Corwin J, Gonzenbach S, Rotrosen JP. Effects of D-cycloserine on negative symptoms in schizophrenia. Schizophr Res. 2004 Dec 1;71(2-3):239-48. Review.</citation>
    <PMID>15474895</PMID>
  </reference>
  <reference>
    <citation>Erhardt S, Schwieler L, Nilsson L, Linderholm K, Engberg G. The kynurenic acid hypothesis of schizophrenia. Physiol Behav. 2007 Sep 10;92(1-2):203-9. Epub 2007 May 21.</citation>
    <PMID>17573079</PMID>
  </reference>
  <reference>
    <citation>Evins AE, Fitzgerald SM, Wine L, Rosselli R, Goff DC. Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry. 2000 May;157(5):826-8.</citation>
    <PMID>10784481</PMID>
  </reference>
  <reference>
    <citation>Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT. D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry. 1996 Dec;153(12):1628-30.</citation>
    <PMID>8942463</PMID>
  </reference>
  <reference>
    <citation>Goff DC, Henderson DC, Evins AE, Amico E. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry. 1999 Feb 15;45(4):512-4.</citation>
    <PMID>10071726</PMID>
  </reference>
  <reference>
    <citation>Heinzen EL, Radtke RA, Urban TJ, Cavalleri GL, Depondt C, Need AC, Walley NM, Nicoletti P, Ge D, Catarino CB, Duncan JS, Kasperaviciūte D, Tate SK, Caboclo LO, Sander JW, Clayton L, Linney KN, Shianna KV, Gumbs CE, Smith J, Cronin KD, Maia JM, Doherty CP, Pandolfo M, Leppert D, Middleton LT, Gibson RA, Johnson MR, Matthews PM, Hosford D, Kälviäinen R, Eriksson K, Kantanen AM, Dorn T, Hansen J, Krämer G, Steinhoff BJ, Wieser HG, Zumsteg D, Ortega M, Wood NW, Huxley-Jones J, Mikati M, Gallentine WB, Husain AM, Buckley PG, Stallings RL, Podgoreanu MV, Delanty N, Sisodiya SM, Goldstein DB. Rare deletions at 16p13.11 predispose to a diverse spectrum of sporadic epilepsy syndromes. Am J Hum Genet. 2010 May 14;86(5):707-18. doi: 10.1016/j.ajhg.2010.03.018. Epub 2010 Apr 15.</citation>
    <PMID>20398883</PMID>
  </reference>
  <reference>
    <citation>Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry. 1996 Nov;169(5):610-7.</citation>
    <PMID>8932891</PMID>
  </reference>
  <reference>
    <citation>Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry. 1999 Jan;56(1):29-36.</citation>
    <PMID>9892253</PMID>
  </reference>
  <reference>
    <citation>Heresco-Levy U, Ermilov M, Lichtenberg P, Bar G, Javitt DC. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry. 2004 Jan 15;55(2):165-71.</citation>
    <PMID>14732596</PMID>
  </reference>
  <reference>
    <citation>Javitt DC. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol. 2007;78:69-108. Review.</citation>
    <PMID>17349858</PMID>
  </reference>
  <reference>
    <citation>Javitt DC, Silipo G, Cienfuegos A, Shelley AM, Bark N, Park M, Lindenmayer JP, Suckow R, Zukin SR. Adjunctive high-dose glycine in the treatment of schizophrenia. Int J Neuropsychopharmacol. 2001 Dec;4(4):385-91.</citation>
    <PMID>11806864</PMID>
  </reference>
  <reference>
    <citation>Jensen JE, Licata SC, Ongür D, Friedman SD, Prescot AP, Henry ME, Renshaw PF. Quantification of J-resolved proton spectra in two-dimensions with LCModel using GAMMA-simulated basis sets at 4 Tesla. NMR Biomed. 2009 Aug;22(7):762-9.</citation>
    <PMID>19388001</PMID>
  </reference>
  <reference>
    <citation>Kaufman MJ, Prescot AP, Ongur D, Evins AE, Barros TL, Medeiros CL, Covell J, Wang L, Fava M, Renshaw PF. Oral glycine administration increases brain glycine/creatine ratios in men: a proton magnetic resonance spectroscopy study. Psychiatry Res. 2009 Aug 30;173(2):143-9. Epub 2009 Jun 24.</citation>
    <PMID>19556112</PMID>
  </reference>
  <reference>
    <citation>Lane HY, Liu YC, Huang CL, Chang YC, Liau CH, Perng CH, Tsai GE. Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol Psychiatry. 2008 Jan 1;63(1):9-12. Epub 2007 Jul 20.</citation>
    <PMID>17659263</PMID>
  </reference>
  <reference>
    <citation>Lin CH, Lane HY, Tsai GE. Glutamate signaling in the pathophysiology and therapy of schizophrenia. Pharmacol Biochem Behav. 2012 Feb;100(4):665-77. doi: 10.1016/j.pbb.2011.03.023. Epub 2011 Apr 1. Review.</citation>
    <PMID>21463651</PMID>
  </reference>
  <reference>
    <citation>Malhotra D, McCarthy S, Michaelson JJ, Vacic V, Burdick KE, Yoon S, Cichon S, Corvin A, Gary S, Gershon ES, Gill M, Karayiorgou M, Kelsoe JR, Krastoshevsky O, Krause V, Leibenluft E, Levy DL, Makarov V, Bhandari A, Malhotra AK, McMahon FJ, Nöthen MM, Potash JB, Rietschel M, Schulze TG, Sebat J. High frequencies of de novo CNVs in bipolar disorder and schizophrenia. Neuron. 2011 Dec 22;72(6):951-63. doi: 10.1016/j.neuron.2011.11.007.</citation>
    <PMID>22196331</PMID>
  </reference>
  <reference>
    <citation>Martínez A, Hillyard SA, Dias EC, Hagler DJ Jr, Butler PD, Guilfoyle DN, Jalbrzikowski M, Silipo G, Javitt DC. Magnocellular pathway impairment in schizophrenia: evidence from functional magnetic resonance imaging. J Neurosci. 2008 Jul 23;28(30):7492-500. Erratum in: J Neurosci. 2008 Sep;28(37):9319.</citation>
    <PMID>18650327</PMID>
  </reference>
  <reference>
    <citation>McCarthy SE, Makarov V, Kirov G, Addington AM, McClellan J, Yoon S, Perkins DO, Dickel DE, Kusenda M, Krastoshevsky O, Krause V, Kumar RA, Grozeva D, Malhotra D, Walsh T, Zackai EH, Kaplan P, Ganesh J, Krantz ID, Spinner NB, Roccanova P, Bhandari A, Pavon K, Lakshmi B, Leotta A, Kendall J, Lee YH, Vacic V, Gary S, Iakoucheva LM, Crow TJ, Christian SL, Lieberman JA, Stroup TS, Lehtimäki T, Puura K, Haldeman-Englert C, Pearl J, Goodell M, Willour VL, Derosse P, Steele J, Kassem L, Wolff J, Chitkara N, McMahon FJ, Malhotra AK, Potash JB, Schulze TG, Nöthen MM, Cichon S, Rietschel M, Leibenluft E, Kustanovich V, Lajonchere CM, Sutcliffe JS, Skuse D, Gill M, Gallagher L, Mendell NR; Wellcome Trust Case Control Consortium, Craddock N, Owen MJ, O'Donovan MC, Shaikh TH, Susser E, Delisi LE, Sullivan PF, Deutsch CK, Rapoport J, Levy DL, King MC, Sebat J. Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet. 2009 Nov;41(11):1223-7. Epub 2009 Oct 25.</citation>
    <PMID>19855392</PMID>
  </reference>
  <reference>
    <citation>Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry. 1995 Dec;52(12):998-1007.</citation>
    <PMID>7492260</PMID>
  </reference>
  <reference>
    <citation>Ongür D, Jensen JE, Prescot AP, Stork C, Lundy M, Cohen BM, Renshaw PF. Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania. Biol Psychiatry. 2008 Oct 15;64(8):718-26. Epub 2008 Jul 7.</citation>
    <PMID>18602089</PMID>
  </reference>
  <reference>
    <citation>Prescot AP, de B Frederick B, Wang L, Brown J, Jensen JE, Kaufman MJ, Renshaw PF. In vivo detection of brain glycine with echo-time-averaged (1)H magnetic resonance spectroscopy at 4.0 T. Magn Reson Med. 2006 Mar;55(3):681-6.</citation>
    <PMID>16453318</PMID>
  </reference>
  <reference>
    <citation>Sebat J, Levy DL, McCarthy SE. Rare structural variants in schizophrenia: one disorder, multiple mutations; one mutation, multiple disorders. Trends Genet. 2009 Dec;25(12):528-35. Epub 2009 Oct 31. Review.</citation>
    <PMID>19883952</PMID>
  </reference>
  <reference>
    <citation>Tsai GE, Lin PY. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des. 2010;16(5):522-37. Review.</citation>
    <PMID>19909229</PMID>
  </reference>
  <reference>
    <citation>Tsai GE, Yang P, Chung LC, Tsai IC, Tsai CW, Coyle JT. D-serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry. 1999 Nov;156(11):1822-5.</citation>
    <PMID>10553752</PMID>
  </reference>
  <reference>
    <citation>Tsai G, Yang P, Chung LC, Lange N, Coyle JT. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 1998 Dec 1;44(11):1081-9.</citation>
    <PMID>9836012</PMID>
  </reference>
  <reference>
    <citation>Tsai G, Lane HY, Yang P, Chong MY, Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 2004 Mar 1;55(5):452-6.</citation>
    <PMID>15023571</PMID>
  </reference>
  <reference>
    <citation>Tsai GE, Yang P, Chang YC, Chong MY. D-alanine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 2006 Feb 1;59(3):230-4. Epub 2005 Sep 9.</citation>
    <PMID>16154544</PMID>
  </reference>
  <reference>
    <citation>van Berckel BN, Evenblij CN, van Loon BJ, Maas MF, van der Geld MA, Wynne HJ, van Ree JM, Kahn RS. D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study. Neuropsychopharmacology. 1999 Aug;21(2):203-10.</citation>
    <PMID>10432468</PMID>
  </reference>
  <reference>
    <citation>Weiss LA, Shen Y, Korn JM, Arking DE, Miller DT, Fossdal R, Saemundsen E, Stefansson H, Ferreira MA, Green T, Platt OS, Ruderfer DM, Walsh CA, Altshuler D, Chakravarti A, Tanzi RE, Stefansson K, Santangelo SL, Gusella JF, Sklar P, Wu BL, Daly MJ; Autism Consortium. Association between microdeletion and microduplication at 16p11.2 and autism. N Engl J Med. 2008 Feb 14;358(7):667-75. Epub 2008 Jan 9.</citation>
    <PMID>18184952</PMID>
  </reference>
  <reference>
    <citation>Wonodi I, Schwarcz R. Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia. Schizophr Bull. 2010 Mar;36(2):211-8. doi: 10.1093/schbul/sbq002. Epub 2010 Feb 10. Review.</citation>
    <PMID>20147364</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 2, 2014</lastchanged_date>
  <firstreceived_date>October 30, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mclean Hospital</investigator_affiliation>
    <investigator_full_name>Deborah L. Levy</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Glycine</keyword>
  <keyword>Glycine decarboxylase</keyword>
  <keyword>Psychosis</keyword>
  <keyword>Mutation</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glycine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
